logo-loader
MaxCyte

MaxCyte appoints Infinity Pharma's Claudio Dansky Ullmann as its chief medical officer

Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals Inc, where he oversaw all clinical development and operations

agreement
MaxCyte said Ullmann will be responsible for overseeing clinical development of MaxCyte’s CARMA drug development program

MaxCyte Inc (LON:MXCT) has announced the appointment of Claudio Dansky Ullmann as its chief medical officer, as the firm prepares for clinical testing of its first cell therapy drug candidate.

The AIM-listed company said in his new role, Ullmann will be responsible for overseeing clinical development of MaxCyte’s CARMA drug development program, with the company’s first candidate, MCY-M11, is expected to enter the clinic this year.

READ: MaxCyte reports strong growth in cash and total assets in 2017 as revenues increase by 14%

The global cell-based medicines and life sciences company said Ullmann brings more than 25 years of experience in clinical oncology and drug development.

He was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where he oversaw all clinical development and operations, shaped corporate strategy and was directly involved in business development activities.

He also worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) and held research roles at the National Institute of Health.

Doug Doerfler, MaxCyte’s CEO, said: “His broad experience in cancer therapy drug development will be invaluable at this stage in MaxCyte’s evolution form a cell engineering technology company to a drug developer with a pipeline of CARMA drug candidate programs.”

The CEO added: “Furthermore, with his deep understanding of the development of immune-oncology therapies and other cancer treatments, Claudio will help us to advance our Flow Electroporation technology to enable our partners to make important medical.

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £69.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read